Published in Cancer Weekly, April 6th, 2010
The trial will compare the pharmacokinetics of CyDex's CDX-353: Propylene Glycol-Free Melphalan HCL for Injection with Alkeran for Injection and evaluate safety parameters. CyDex is working in partnership with The University of Kansas Cancer Center on the trial, which will be partially funded by a grant the company received from the Kansas Bioscience...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.